344 related articles for article (PubMed ID: 8620488)
1. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.
Adachi M; Taki T; Ieki Y; Huang CL; Higashiyama M; Miyake M
Cancer Res; 1996 Apr; 56(8):1751-5. PubMed ID: 8620488
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of CD151 gene expression in non-small cell lung cancer.
Tokuhara T; Hasegawa H; Hattori N; Ishida H; Taki T; Tachibana S; Sasaki S; Miyake M
Clin Cancer Res; 2001 Dec; 7(12):4109-14. PubMed ID: 11751509
[TBL] [Abstract][Full Text] [Related]
3. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer.
Higashiyama M; Taki T; Ieki Y; Adachi M; Huang CL; Koh T; Kodama K; Doi O; Miyake M
Cancer Res; 1995 Dec; 55(24):6040-4. PubMed ID: 8521390
[TBL] [Abstract][Full Text] [Related]
4. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
5. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma.
Uchida S; Shimada Y; Watanabe G; Li ZG; Hong T; Miyake M; Imamura M
Br J Cancer; 1999 Mar; 79(7-8):1168-73. PubMed ID: 10098753
[TBL] [Abstract][Full Text] [Related]
6. KAI1/CD82 expression as a prognosic factor in sporadic colorectal cancer.
Muneyuki T; Watanabe M; Yamanaka M; Shiraishi T; Isaji S
Anticancer Res; 2001; 21(5):3581-7. PubMed ID: 11848527
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model.
Takeda T; Hattori N; Tokuhara T; Nishimura Y; Yokoyama M; Miyake M
Cancer Res; 2007 Feb; 67(4):1744-9. PubMed ID: 17308116
[TBL] [Abstract][Full Text] [Related]
8. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression.
Adachi M; Taki T; Konishi T; Huang CI; Higashiyama M; Miyake M
J Clin Oncol; 1998 Apr; 16(4):1397-406. PubMed ID: 9552043
[TBL] [Abstract][Full Text] [Related]
9. KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ; Lu CH; Chiou LC
Clin Cancer Res; 2003 Apr; 9(4):1393-8. PubMed ID: 12684410
[TBL] [Abstract][Full Text] [Related]
10. KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese.
Hu WL; Li YQ; He HX; Li QR; Tian Y; Lai RQ; Mei H
Asian J Androl; 2000 Sep; 2(3):221-4. PubMed ID: 11225981
[TBL] [Abstract][Full Text] [Related]
11. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
12. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis.
Higashiyama M; Kodama K; Yokouchi H; Takami K; Adachi M; Taki T; Ishiguro S; Nakamori S; Yoshie O; Miyake M
Cancer; 1998 Aug; 83(3):466-74. PubMed ID: 9690539
[TBL] [Abstract][Full Text] [Related]
13. CD82, and CD63 in thyroid cancer.
Chen Z; Mustafa T; Trojanowicz B; Brauckhoff M; Gimm O; Schmutzler C; Köhrle J; Holzhausen HJ; Kehlen A; Klonisch T; Finke R; Dralle H; Hoang-Vu C
Int J Mol Med; 2004 Oct; 14(4):517-27. PubMed ID: 15375577
[TBL] [Abstract][Full Text] [Related]
14. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer.
Miyake M; Nakano K; Itoi SI; Koh T; Taki T
Cancer Res; 1996 Mar; 56(6):1244-9. PubMed ID: 8640807
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival.
Farhadieh RD; Smee R; Ow K; Yang JL; Russell PJ; Crouch R; Jackson P; Jacobson IV
Cancer Lett; 2004 Sep; 213(1):91-8. PubMed ID: 15312688
[TBL] [Abstract][Full Text] [Related]
16. Loss of KAI1 expression in the progression of colorectal cancer.
Lombardi DP; Geradts J; Foley JF; Chiao C; Lamb PW; Barrett JC
Cancer Res; 1999 Nov; 59(22):5724-31. PubMed ID: 10582691
[TBL] [Abstract][Full Text] [Related]
17. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.
Huang CI; Kohno N; Ogawa E; Adachi M; Taki T; Miyake M
Am J Pathol; 1998 Sep; 153(3):973-83. PubMed ID: 9736046
[TBL] [Abstract][Full Text] [Related]
18. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells.
Zhang XA; Lane WS; Charrin S; Rubinstein E; Liu L
Cancer Res; 2003 May; 63(10):2665-74. PubMed ID: 12750295
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma.
Guo C; Liu QG; Zhang L; Song T; Yang X
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):389-96. PubMed ID: 19666408
[TBL] [Abstract][Full Text] [Related]
20. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
